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EFFECT OF A CASEIN HYDROLYSATE CONTAINING NOVEL PEPTIDES IN 
HYPERTENSIVE SUBJECTS 
INTRODUCTION 
Enzymatic hydrolysis of food proteins is an efficiently strategy to produce biological active 
peptides. Our group identified two alphas1-casein fragments with potent angiotensin-converting 
enzyme-inhibitory activity in vitro and antihypertensive effect and additional cardiovascular 
benefits in spontaneously hypertensive rats (SHR). Therefore, these results might be translated 
to humans to consider these peptides as a functional food ingredient to prevent hypertension 
with additional cardiovascular benefits. 
OBJETIVES 
To evaluate the antihypertensive activity of a food-grade ingredient containing novel peptide 
sequences in humans. 
METHOD/DESIGN 
"Stability of the ingredient to atomisation, pasteurisation, incorporation to fermented products 
and dose in the different batches prepared for the human trial was evaluated by mass 
spectrometry". The human trial was developed using a yoghurt drink enriched with the 
hydrolysate. A total of 71 hypertensive subjects (placebo and active substance groups) and 50 
normotensive volunteers (only active substance) were enrolled. All subjects consumed one 
liquid yogurt (150 ml) per day during 6 weeks. 
RESULTS 
The active peptides were stable during the processes of atomization, homogenization and 
pasteurization. When the hydrolysate was incorporated into liquid yoghurt, no significant 
reduction of peptides was detected during the shelf-life of the product. The amount of the active 
peptides in the ingredient was between 2.5-3.1 mg/g hydrolysate, and the dose of active peptides 
administered during the trial ranged between 5.8 to 7.3 mg. After 6 weeks of consuming the 
yogurt containing the active ingredient, the hypertense patients showed a change in their 
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systolic blood pressure of -12.5 mmHg with a confidence interval between 4.7 and 20.2 mmHg 
(pd0.05). It has to be highlighted that no significant changes in blood pressure were detected in 
both the placebo and the normotensive groups. 
CONCLUSIONS 
The beneficial effect of an active casein hydrolysate on hypertensive subjects has been 
demonstrated. 
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